MNG785
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.490
- MYC_TARGETS_V1+0.455
- DNA_REPAIR+0.380
- PEROXISOME+0.370
- ADIPOGENESIS+0.365
- FATTY_ACID_METABOLISM+0.316
- MTORC1_SIGNALING+0.305
- BILE_ACID_METABOLISM+0.285
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.250
- MYC_TARGETS_V2+0.235
Top 10 suppressed
- MITOTIC_SPINDLE-0.394
- UV_RESPONSE_DN-0.343
- WNT_BETA_CATENIN_SIGNALING-0.342
- TGF_BETA_SIGNALING-0.327
- NOTCH_SIGNALING-0.320
- TNFA_SIGNALING_VIA_NFKB-0.282
- IL6_JAK_STAT3_SIGNALING-0.246
- HEDGEHOG_SIGNALING-0.225
- INFLAMMATORY_RESPONSE-0.210
- KRAS_SIGNALING_DN-0.195
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | e84aa97b-e429-4994-acef-2b57be71fe9a | — | — | 0.844 |
| 2 | 054d5602-4089-4f34-a667-14c8edbb4167 | — | — | 0.804 |
| 3 | TCGA-37-4133-01A-01R-1100-07 | — | cohortSQ1 | 0.804 |
| 4 | 94a92a4a-6c40-40c4-913d-0cdba8cb5892 | — | — | 0.803 |
| 5 | 2d83a9e6-da2d-47e1-b2e7-4b07b108f7bd | — | — | 0.800 |
| 6 | 48128da3-329b-45c5-be65-c8cbeccddb97 | — | — | 0.796 |
| 7 | TCGA-E2-A14O-01A-31R-A115-07 | — | B | 0.789 |
| 8 | SRR13311171 | — | — | 0.780 |
| 9 | SRR8518248 | — | E | 0.780 |
| 10 | f844415e-ca2a-4837-b050-06775fdb2ed5 | — | — | 0.776 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.490 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.455 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.380 | Idelalisib | — uncovered |
| PEROXISOME | 0.370 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.365 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.316 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.305 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.285 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.250 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.235 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.213 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.205 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.185 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.185 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.168 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.138 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.123 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.119 | Temsirolimus | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.112 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |